Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 inhibitor + axitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PD-1 inhibitor + axitinib refers to the combination of a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor (such as pembrolizumab or toripalimab) with axitinib, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs). This combination is used primarily for the treatment of advanced renal cell carcinoma and has also shown activity in metastatic mucosal melanoma. The PD-1 inhibitor blocks the interaction between PD-1 on T cells and its ligands, enhancing anti-tumor immune responses. Axitinib inhibits angiogenesis by selectively blocking VEGFR 1–3 signaling pathways, thereby reducing tumor blood supply and growth. The combination leverages both immunomodulatory and antiangiogenic mechanisms to improve clinical outcomes in cancer patients[6][4][5].
- Brand names
- TuoyiBaizeanKeytrudaInlyta
- Other names
- toripalimabtislelizumabpembrolizumabaxitinibICI + axitinibimmune checkpoint inhibitor + axitinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 inhibitor + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 inhibitor + axitinib.